ENTA News and Press, Enanta Pharmaceuticals Inc. From 03/08/23

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presen...

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33 rd Annual Healthcare Confer...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Enanta Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2023 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Jennifer Viera – Investor Relations Jay Luly – President and Chief Executive Officer Paul Mellett – Chief Financial Officer Ta...

Enanta Pharma press release ( NASDAQ: ENTA ): Q1 GAAP EPS of -$1.39 beats by $0.16 . Revenue of $23.6M (-14.6% Y/Y) beats by $1.12M . Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $241.4 million at December 31, 2022. ...

Completes Enrollment in SPRINT, a Phase 2 Clinical Study of EDP-235, a 3CL Protease Inhibitor Designed as an Oral, Once-Daily Treatment for COVID-19; Topline Data Expected in May Expects Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Re...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biop...

Enanta Pharma ( NASDAQ: ENTA ) is scheduled to announce Q1 earnings results on Tuesday, February 7th, after market close. The consensus EPS Estimate is -$1.60 (-8.1% Y/Y) and the consensus Revenue Estimate is $22.48M (-18.7% Y/Y). Over the last 1 year, ENTA has beaten EPS es...

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes o...

Progresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023 Presents New Preclinical In Vivo Data Demonstrating EDP-235’s Efficacy and Prevention of COVID-19 Transmission Expands Robust COVID-19 Antiviral Portfolio...